The real revolution came in 2012, when researchers Jennifer Doudna and Emmanuelle Charpentier harnessed CRISPR, a natural bacterial defense system. In bacteria, CRISPR cuts out invading viruses’ DNA ...

Reviving an ancient human gene that prevents gout and fatty liver disease, scientists at Georgia State University have marked ...

CRISPR-based technology is advancing rapidly, driving international competition. Its promise to transform medicine is colliding with political and social realities, even as applications expand.

According to the 13F filing with the Securities and Exchange Commission dated Nov. 12, 2025, ARK Investment Management sold ...

By reactivating a long-lost gene, researchers were able to lower uric acid levels and stop damaging fat accumulation in human ...

Promising results from a small clinical trial highlight a growing interest in designing gene-editing treatments for common ...

CRISPR Therapeutics AG is rated a Buy with $1.9B cash, prudent management, and undervalued shares. Learn more about CRSP ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Access to ERS Genomics’ foundational CRISPR/Cas9 patent portfolio expands our genetic engineering toolkit and strengthens our ability to speed up and optimize strain development across Dyadic’s ...

The FDA’s Marty Makary and Vinay Prasad have laid out a path for CRISPR treatments on demand. An expert weighs in on what it ...

In a 15-patient, Phase 1, first-in-human trial, a one-time CRISPR-Cas9 gene-editing therapy safely reduced LDL cholesterol ...

Positive Phase 1 data for CTX310® presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions and ...